Phase 3Not yet recruitingPriority 1 · Highest priorityNCT07178457
Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance
Plain-language summary
This Phase 3 trial is comparing Brentuximab Vedotin (Bv) and Placebo against other options for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Brentuximab Vedotin (Bv) (DRUG): 1.8 mg/kg in 100 mlof NaCl 0.9%, Q3W with a maximum of 16 cycles | Placebo (DRUG): NaCl 0.9% 100 ml IV Q3W with a maximum of 16 cycles
- Drugs / treatments
- Brentuximab Vedotin (Bv), Placebo
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details